PATENT CLAIM ANALYSIS

Application Number: 16078054
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "217100"]

Abstract:
Provided are a urea compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an FLT3 tyrosine protein kinase inhibitor, particularly in the prevention and/or treating of cancer.

Claim (Index 3):
The compound of general formula (I) or the pharmaceutically acceptable salt, solvate or prodrug thereof according to  claim 1 ,\n wherein: X, Y, A, and A 1  are selected from the following structures: R 5 1 , R 5 2 , R 5 3 , R 5 4 , R 5 5  are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, \u2014N(R y )(R z ), haloalkyl and haloalkoxy; R 1 , B, R y , R z  are as defined in  claim 1 .

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.15789
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14297790', '13389146', '10939324', '11201823', '12105408']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8271215397598348
- 35 USC 102 Novelty (BERT): 0.5236584216968024
- Combined Prediction Score: 0.7967752279535316
- Mean Citation Score: 335.0989120000001
- Max Citation Score: 349.75607
- Similarity Product: 294.8533919638288

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test